Clinical Sensors, a development-stage biotechnology company based in Research Triangle Park, is developing sensors that can detect and diagnose life-threatening infections and conditions at an early stage. The company seeks to use its patent-pending point-of-care monitoring technology to safely and effectively monitor the levels of nitric oxide in the bloodstream, which is a involved in the progression of sepsis, an imbalance of chemicals in the body which can become life threatening if not properly diagnosed.
Clinical Sensors hopes that with the adoption of its technology by medical practices around the country, one simple blood test will be able ensure a patient’s safety and shorter hospital visits, by providing practitioners rapid recognition information they need, in a matter of seconds.
Mark Schoenfish, distinguished professor of chemistry at UNC-Chapel Hill, wants to demonstrate the clinical capacity for his company’s point-of-care technology as a reliable screening method for sepsis.
Schoenfish founded Clinical Sensors in 2009, having previously founded Novan Therapeutics, a clinical stage company specializing in therapeutic applications of nitric oxide’s naturally occurring anti-microbial and noninflammatory mechanisms.
Schoenfish hoped to leverage the research conducted at Novan to better understand the molecule and its role in the progression of sepsis, with hopes to develop sensing technology that could detect raising nitric oxide levels in the blood for use in diagnosis.
Read the full story via the North Carolina Business News Wire, a service of the UNC-Chapel Hill School of Media and Journalism.
| UNC-CH